Medtech product launch: a PR plan for medical device companies

A medtech product launch is a regulatory event before it is a media event. What you can say, when you can say it and who you can say it to all depend on where your device sits in the FDA, UK or EU process, and one wrong word in a press release (calling a cleared device “approved”, say) is the kind of mistake trade journalists spot and regulators treat as misbranding.

This guide sets out a PR plan for a medical device product launch: the wording rules, what you can say before clearance, how to handle clinical data and embargoes, who to pitch, a timeline you can work to and how to use clinicians as spokespeople. It is written for founders, marketers and clinical leads at device companies who want coverage that helps sales and survives a regulatory review.

What makes a medtech product launch different?

Most product launches are built around a date the company chooses. A medical device launch is built around a decision the company doesn’t control: clearance, approval or a conformity marking. Until that decision arrives, you can’t market the product, and the claims you make afterwards are limited to what the regulator has signed off.

Three other things set medtech apart:

• Several audiences, each with a different evidence bar. Clinicians want data and the exact indication. Hospital buyers want workflow and cost. Investors and business press want the market story. Patients, if they use or choose the device, want to know whether it is for them.
• Long sales cycles. Coverage on launch day rarely closes a sale. It earns a place on a shortlist, so the PR has to keep working for months.
• Coverage is part of your claims footprint. If a journalist misstates your indication and you share the article on your own channels, you now own that claim.

That is why our product launch PR work for device companies starts with the regulatory status and the approved wording, not the media list.

Cleared, approved or registered? Getting the regulatory wording right

In the US, the verb depends on the pathway. The FDA describes a 510(k) as a premarket submission showing that a device is as safe and effective as a legally marketed predicate device. When the FDA agrees the device is substantially equivalent, its order “clears” the device for commercial distribution. The FDA’s 510(k) page also says the submission must be made at least 90 days before the device is offered for sale, and that the device can’t be marketed until the clearance order arrives.

Premarket approval (PMA) is different. The FDA calls it “the most stringent type of device marketing application”, used for Class III devices, and the applicant must receive FDA approval of the PMA before marketing. So “FDA-approved” is correct for a PMA device and wrong for a 510(k) device.

The regulations are explicit about the second point. Under 21 CFR 807.97, a 510(k) and a finding of substantial equivalence do not mean the FDA has officially approved the device, and any representation that creates that impression is misleading and counts as misbranding. Under 21 CFR 807.39, registering an establishment or holding a registration number doesn’t denote approval either, and implying official endorsement because of it is also misbranding.

Brief your spokespeople on the right verb and put it in every document: the release, the Q&A, the website and the social posts. When a journalist writes “approved” for a cleared device, ask for a correction. It is a small fix and most editors will make it.

What can you say before clearance?

Less than founders hope, but more than nothing. Under 21 CFR 812.7, a sponsor, an investigator or anyone acting for them may not promote or test-market an investigational device before the FDA has approved it for commercial distribution, and may not represent that it is safe or effective for the purposes being studied. A device going through the 510(k) route can’t be marketed until it is cleared.

The FDA’s 1999 guidance on notices of availability of investigational devices shows how narrow the permitted channel is. Notices recruiting investigators should run only in medical or scientific publications or at meetings whose audiences are mainly qualified experts, should say their only purpose is to find investigators, and should be limited to the proposed use, the sponsor’s name and address, how to apply and how to obtain the device. They must carry the statement “Investigational device, limited by Federal (or United States) law to investigational use”, and may not imply the device is safe, effective or better than another device.

What that leaves for pre-clearance PR:

• The company story: the founders, the clinical problem, funding and hiring, kept free of performance claims about the device.
• The problem story: clinician commentary on the unmet need, without pointing readers to your product as the answer.
• Science at scientific meetings: study presentations to expert audiences, handled under the meeting’s embargo rules (see below).

Have regulatory counsel review every pre-clearance announcement. A funding release that slips in “the first device to cure” is still promotion.

Launching in the UK and EU

In the EU, Article 7 of the Medical Devices Regulation (EU) 2017/745 governs claims. In labelling, instructions for use, making available, putting into service and advertising, it bans text, names, trade marks, pictures and other signs that may mislead users or patients about a device’s intended purpose, safety and performance, by:

• giving the device functions or properties it doesn’t have;
• creating a false impression about treatment or diagnosis, or about functions or properties the device doesn’t have;
• failing to tell the user or patient about a likely risk of using the device as intended;
• suggesting uses beyond the intended purpose that the conformity assessment covered.

In practice, the indication in your press release should match the intended purpose on your certificate word for word, and the risks shouldn’t be left out of the patient-facing story.

For Great Britain, the MHRA’s guidance (updated 20 February 2026) says you must register devices with the MHRA before placing them on the market, and manufacturers outside the UK must appoint a UK Responsible Person. CE-marked devices remain accepted for now: devices certified under the EU MDR or IVDR until 30 June 2030, and general devices under the older EU directives until their certificate expires or 30 June 2028, whichever is sooner. The UKCA mark isn’t recognised in the EU, and Northern Ireland requires CE marking.

If you plan a UK launch with ads or influencer content alongside the press work, our guide to health claims and PR compliance covers how the ASA treats device advertising.

Clinical data, journals and embargoes

If your launch story rests on a trial, the publication plan and the PR plan have to be one plan. Get the order wrong and you can jeopardise the paper.

The International Committee of Medical Journal Editors (ICMJE) says sharing accepted but unpublished findings with the media breaches the policies of many journals, and any such reporting should be agreed with the editor in advance. Press reports of scheduled meeting presentations aren’t usually treated as prior publication, but they can be if extra data tables or figures are added. The ICMJE also says researchers who present at a meeting should feel free to discuss the talk with reporters, but should be discouraged from giving more detail than they presented.

Embargoes run on trust. The ICMJE notes the system “works on the honor system”, with no formal enforcement. Services such as EurekAlert! add their own terms: reporters agree to hold embargoed news until the release time, and a breach can lead to suspension of access for the reporter and, where applicable, everyone at their news organisation. Its agreement now also bars uploading embargoed material to AI tools.

Medical conferences set their own rules, and they can be strict. As one example, the American College of Cardiology’s 2023 meeting policy embargoed late-breaking trials until the start of the session in which they were presented, barred releases containing embargoed information until the embargo lifted, asked for releases mentioning the meeting to be submitted for approval at least a week ahead, and treated discussing results at industry events, press conferences or media interviews before the presentation as an embargo break, with sanctions including removal of the research from the programme. Check the current policy of your meeting well before you write the release.

The practical plan: draft the release and the briefing pack while the paper is in review, offer embargoed briefings to a short list of reporters, and time the release to the moment the paper or presentation goes public.

Who should you pitch for a medical device launch?

Pitch by audience, with an angle built for each:

• Medtech trade and business press: the regulatory pathway, the market, the funding, the competitive context and the commercial plan.
• Clinician and specialty press: the data, the exact indication, how the device fits into existing practice and what it changes for the care team.
• Health desks at national and consumer titles: only if patients use, choose or ask for the device. Lead with the condition and a clinician’s voice, not the product.
• Regional press: the first hospital to use the device, a local manufacturing story or a local clinician who led the study.

Consumer-facing health devices can reach a wider audience through expert commentary. When we worked with Omhale, a breathing trainer, the coverage was led by Elizabeth Moffett, a registered respiratory therapist and certified asthma educator, and earned seven placements in about six weeks in October and November 2025, including Men’s Journal (syndicated to Yahoo Health) and the Peloton blog. You can read the Omhale case study for how it ran.

For broader medtech PR, the same rule applies across every outlet: one clear angle per journalist, the approved wording in every asset and a spokesperson ready on launch day.

A medtech launch timeline: pre-launch, launch and post-launch

Here is a seven-step launch plan you can adapt to your pathway. Timings run from the expected regulatory decision, which can move, so build the plan around milestones rather than fixed dates.

1. Map the regulatory status and build a claims matrix (during the review). List every claim you want to make, the evidence for each, and the exact approved wording for each market.
2. Agree the publication and conference plan. Decide where the data will appear first and what each embargo allows.
3. Run the pre-clearance story. Company, founders and the clinical problem, with no product performance claims.
4. Prepare the launch pack. Release, Q&A, indication statement, images, clinician and patient spokespeople (with consent), all signed off by regulatory and medical review.
5. Brief under embargo. Offer a small number of trade and clinical reporters early access, timed to the decision or the publication.
6. Launch. Announce on the day of clearance, approval or the data going public, with spokespeople available for the first 48 hours.
7. Sustain it. Follow with first-site stories, conference presentations, real-world experience and expert commentary over the next six to twelve months.

Some device companies start with a limited market release: a controlled rollout to a few sites before full launch. For PR, that phase is usually quiet in public, but it is where you gather the clinician experience and site stories that make the full launch credible.

Decide before launch what you will measure: coverage in the outlets your buyers read, links to the product page, demo requests and enquiries. Our guide to measuring health PR sets out a reporting template.

Working with clinicians as spokespeople

A clinician who used the device in the study is the most credible voice you have, and the one with the most rules attached. The AdvaMed Code of Ethics, which guides medical technology companies on their relationships with health care professionals, was updated with changes effective 1 November 2025. Its consulting provisions say companies should engage a clinician only for a legitimate need identified in advance, choose them on their qualifications, set out the services in a written contract and pay fair market value that isn’t linked to the volume or value of their business. Speaking services count as consulting, and when clinicians speak on a company’s behalf, audiences should be told they are presenting for the company and paid by it.

For PR, that means:

• disclose any paid relationship when a clinician talks to the media about your device;
• keep their comments within the approved indication, because the FTC says advertisers are liable for the misleading use of endorsements;
• offer independent clinicians, with no ties to you, as additional voices when journalists ask for them, and don’t try to steer what they say;
• train every spokesperson on the approved wording, the evidence and the questions they shouldn’t answer.

If your device is aimed at a specific patient group, our guide to PR for femtech and women’s health startups shows how condition-led stories work with clinician voices.

This guide is general information, not legal advice.